PMID- 12616107
OWN - NLM
STAT- MEDLINE
DCOM- 20030926
LR  - 20191106
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 26
IP  - 2
DP  - 2003 Mar-Apr
TI  - Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in 
      patients with resected stage III and IV melanoma.
PG  - 156-62
AB  - Adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) and interleukin 
      (IL)-2 is reasonably effective in the treatment of patients with advanced 
      melanoma. However, theoretically it should be of greater benefit as adjuvant 
      therapy, especially in high-risk stages (resected stages III and IV). In a 
      preliminary study, 25 patients (aged 23-72 years) with stage III-IV melanoma who 
      underwent resection of metachronous metastases were reinfused with TIL cultivated 
      and expanded in vitro with IL-2 from surgically removed metastases. IL-2 
      (starting dose 12 x 10 IU/m ) was co-administered as a continuous infusion 
      according to West's scheme. A total of 8/22 (36.3%) evaluable patients were 
      disease-free (DF) at a median follow-up of 5 years. DF survival (DFS) and overall 
      survival (OS) rates were 44% and 37%, respectively, at 2 years, and 52% and 45% 
      at 3 years. The CNS was the only site of disease recurrence in 57% of patients 
      who relapsed. DF patients received a higher median dose of IL-2 than those who 
      progressed (total dose 110 x 10 versus 86 x 10 IU/m, respectively). The 
      progressive reduction in IL-2 dosage allowed all patients to complete treatment 
      without permanent grade 4 toxicity. Analysis of tumor immunosuppression factors 
      in lymphocytes inside the tumor (TCR zeta and epsilon chains, p56, FAS, and 
      FAS-ligand) confirmed that the immunologic potential of TIL, depressed at the 
      time of metastasectomy, was significantly restored after in vitro culture with 
      IL-2. Adoptive immunotherapy with TIL and IL-2 could improve DFS and OS, although 
      further work is required to determine its role in the treatment of patients with 
      high-risk melanoma.
FAU - Ridolfi, Laura
AU  - Ridolfi L
AD  - Istituto Oncologico Romagnola, Pierantoni Hospital, Forli, Italy.
FAU - Ridolfi, Ruggero
AU  - Ridolfi R
FAU - Riccobon, Angela
AU  - Riccobon A
FAU - De Paola, Franca
AU  - De Paola F
FAU - Petrini, Massimiliano
AU  - Petrini M
FAU - Stefanelli, Monica
AU  - Stefanelli M
FAU - Flamini, Emanuela
AU  - Flamini E
FAU - Ravaioli, Alessandra
AU  - Ravaioli A
FAU - Verdecchia, Giorgio Maria
AU  - Verdecchia GM
FAU - Trevisan, Giusto
AU  - Trevisan G
FAU - Amadori, Dino
AU  - Amadori D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage
MH  - Adult
MH  - Aged
MH  - Biopsy, Needle
MH  - Combined Modality Therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Infusions, Intravenous
MH  - Interleukin-2/*administration & dosage
MH  - Lymphocytes, Tumor-Infiltrating/*transplantation
MH  - Male
MH  - Melanoma/mortality/*pathology/surgery/*therapy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Probability
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Skin Neoplasms/mortality/*pathology/surgery/*therapy
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2003/03/05 04:00
MHDA- 2003/09/27 05:00
CRDT- 2003/03/05 04:00
PHST- 2003/03/05 04:00 [pubmed]
PHST- 2003/09/27 05:00 [medline]
PHST- 2003/03/05 04:00 [entrez]
AID - 10.1097/00002371-200303000-00008 [doi]
PST - ppublish
SO  - J Immunother. 2003 Mar-Apr;26(2):156-62. doi: 10.1097/00002371-200303000-00008.